摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

guanosine 3'-monophosphate | 117771-36-5

中文名称
——
中文别名
——
英文名称
guanosine 3'-monophosphate
英文别名
guanosine-3'-monophosphate(2-);3'-guanosinemonophosphate dianion;Guanosine 3'-monophosphate(2-);[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] phosphate
guanosine 3'-monophosphate化学式
CAS
117771-36-5
化学式
C10H12N5O8P
mdl
——
分子量
361.208
InChiKey
ZDPUTNZENXVHJC-UUOKFMHZSA-L
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -3.7
  • 重原子数:
    24
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    207
  • 氢给体数:
    4
  • 氢受体数:
    10

反应信息

点击查看最新优质反应信息

文献信息

  • Regioselective cleavage of di- and poly-ribonucleotides induced by cyclodextrins (cyclomalto-oligosaccharides)
    作者:Makoto Komiyama
    DOI:10.1016/0008-6215(89)85169-9
    日期:1989.10
    Abstract Cyclodextrins (cyclomalto-oligosaccharides, CDs) induce regioselective cleavage of the 3′,5′-phosphodiester linkages in di- and poly-ribonucleotides at pH 11.08 and 50°. 0.15 m Cyclomaltohexaose (α-CD) mediates the cleavage of CpA, CpC, CpG, and CpU to give 96–97% of cytidine 3′-phosphate together with adenosine, cytidine, guanosine, and uridine, respectively. In the absence of α-CD, 50–52%
    摘要环糊精(环麦芽寡糖,CD)在pH 11.08和50°下诱导二和多核糖核苷酸中3',5'-磷酸二酯键的区域选择性切割。0.15 m的环己二糖(α-CD)介导CpA,CpC,CpG和CpU的裂解,分别产生96–97%的胞苷3'-磷酸以及腺苷,胞苷,鸟苷和尿苷。在没有α-CD的情况下,形成了50-52%的胞苷2'-磷酸副产物。α-CD还促进了ApA和ApC的腺苷3'-磷酸的形成,GpG的鸟苷3'-磷酸的形成和UpU的尿苷3'-磷酸的形成。相反,β-CD和γ-CD增强了相应的2'-磷酸盐的形成。还实现了poly [A],poly [C],poly [G]和poly [U]的区域选择性切割。
  • Hydrolysis of Diribonucleoside Monophosphate Diesters Assisted by a Manganese(II) Complex
    作者:Morio Yashiro、Maiko Higuchi、Makoto Komiyama、Youichi Ishii
    DOI:10.1246/bcsj.76.1813
    日期:2003.9
    An Mn2+ complex with 2,2′:6′,2″-terpyridine (terpy) was found to promote the hydrolysis of NpN (NpN = diribonucleoside monophosphate diester) efficiently at pH 7.0 and 50 °C under ambient conditions. The structure of the Mn2+ complex involving a phosphodiester molecule, [(terpy)(dpp)MnII(μ-dpp)2MnII(dpp)(terpy)], dpp = diphenyl phosphate anion, was established by X-ray crystallography, and the coordination mode of Mn2+ to a phosphodiester molecule was considered.
    在常温常压下,于pH 7.0和50°C条件下,发现一种含2,2′:6′,2″-三联吡啶(terpy)的Mn2+配合物能高效促进NpN(NpN = 二核苷酸单磷酸二酯)的水解。通过X射线结晶学确定了涉及磷酸二酯分子的Mn2+配合物[(terpy)(dpp)MnII(μ-dpp)2MnII(dpp)(terpy)]的结构,其中dpp = 二苯基磷酸盐阴离子,并考虑了Mn2+与磷酸二酯分子的配位方式。
  • Cisplatin−DNA Cross-Link Retro Models with a Chirality-Neutral Carrier Ligand:  Evidence for the Importance of “Second-Sphere Communication”
    作者:Sharon T. Sullivan、Antonella Ciccarese、Francesco P. Fanizzi、Luigi G. Marzilli
    DOI:10.1021/ic000736x
    日期:2001.1.1
    forms) with both G H8 signals unusually downfield encouraged us to study additional Me2ppzPtG2 analogues in order to explain the unusual spectral features and to identify factors that influence the relative stability of HT and HH forms. Molecular modeling techniques suggest HH structures with the H8's close to the deshielding region of the z axis of the magnetically anisotropic Pt atom, explaining
    我们采用逆模型,顺式-PtA2G2(A2 =二胺,G =鸟嘌呤衍生物)来评估被广泛认为是负责任的顺铂-DNA d(GpG)加合物的交联头对头(HH)形式具有抗癌活性。将逆向模型设计为具有最小的动态运动,以克服顺铂[A2 =(NH3)2]衍生的模型中发现的问题;由于溶液中Pt-N7键的G碱基快速旋转以及固体中首尾相(HT)形式的优势,后一种模型难以理解。对于顺式-PtA2G2模型,观察到HH形式是不寻常的。最近,在新的Me2ppzPtG2模型的研究中,我们发现了A2缺少NH基团的cis-PtA2G2模型的第一个HH形式。(Me2ppz,N,N'-二甲基哌嗪,具有平面内体积,当基座从基本垂直于该平面的基态位置旋转到协调平面时,与G6发生碰撞,从而减少了动态运动G = 5'-GMP和3'-GMP。) (尽管有HT形式的混合物)同时具有两种H8信号,但它们在近场异常地激发我们研究更多的Me2ppz
  • Ternary Pt(II)-amino acid-nucleotide complexes: kinetics of formation
    作者:Dan Gibson、Georgia M. Arvanitis、Helen M. Berman
    DOI:10.1016/0020-1693(94)03797-3
    日期:1994.4
    Abstract Ternary complexes of Pt(II) with the nucleotides 5′-GMP, 3′-GMP and 5′-dGMP (GMP=guanosinemonophosphate), and with the amino acids N α -BOC L -histidine, N α -BOC- L -methionine and 1-methylimidazole (1-MeIm) were studied as models for Pt mediated DNA-protein crosslinks. The triamine complexes [PtAm 2 (L)Cl] + (where Am 2 =cis- or trans -(NH 3 ) 2 or ethylenediamine and L=1-MeIm or N α -BOC-
    摘要Pt(II)与核苷酸5'-GMP,3'-GMP和5'-dGMP(GMP =鸟苷一磷酸)以及氨基酸Nα-BOC L-组氨酸,Nα-BOC- L的三元配合物研究了甲硫氨酸和1-甲基咪唑(1-MeIm)作为Pt介导的DNA-蛋白质交联的模型。三胺络合物[PtAm 2(L)Cl] +(其中Am 2 =顺-或反-(NH 3)2或乙二胺和L = 1-MeIm或Nα-BOC-L -his- N 3)容易反应与单核苷酸5'-GMP,3'-GMP和5'-dGMP形成三元交联复合物PtAm 2(L)(核苷酸)。5'核苷酸对任何三胺复合物的反应比其3'对应物反应更快。通过1 H NMR进行的动力学研究表明,顺式-[PtAm 2(1-MeIm-N 3)Cl] +与5'-GMP的反应比反式异构体更快(二阶速率常数k 2 = 0.756和0.358 M -1 s -1,
  • Second-sphere ‘communication’ between two cis-bound guanine nucleotides. Factors influencing conformations of dynamic adducts of cis-type platinum anticancer drugs with guanine nucleotides as deduced by circular dichroism spectroscopy
    作者:Hing C Wong、Kazuo Shinozuka、Giovanni Natile、Luigi G Marzilli
    DOI:10.1016/s0020-1693(99)00256-x
    日期:2000.1
    cis-PtA2G2 (G=guanine derivative, A=NH3, and A2=trimethylenediamine (tn), or ethylenediamine (en)). Each adduct has three possible atropisomers (Δ and ΛHT (head-to-tail) and HH (head-to-head) forms). Recently, we demonstrated using NMR methods that the dynamic motion problem could be minimized by the bulky CCC ligands of (CCC)PtG2 complexes (CCC=chirality-controlling chelate ligand). We identified the atropisomers
    与鸟嘌呤N7结合的Pt抗癌药物的加合物是易变的,无论鸟嘌呤是较大物种(如DNA)还是较小类似物(如3'-或5'-鸟苷单磷酸(3'-或5'-GMP)的一部分)。这种动态运动问题使NMR方法无法揭示此处研究的简单加合物顺式-PtA 2 G 2(G =鸟嘌呤衍生物,A = NH 3和A 2 =三亚甲基二胺(tn)或乙二胺)的溶液构象。(zh))。每个加合物具有三种可能的阻转异构体(Δ和ΛHT(头对尾)和HH(头对头)形式)。最近,我们证明了使用NMR方法可以通过(CCC)Pt G 2配合物的大体积CCC配体(CCC =控制手性的螯合配体)使动态运动问题最小化。我们鉴定了阻转异构体并确定了其构象。我们表明主要HT形式的手性与混合物的CD峰的符号相关。在本研究中,CD光谱用于评估动态顺式-PtA 2 G 2加合物的主要HT阻转异构体的构象。所有简单的顺式-PtA检查的2个G 2加合物对于G= 3′-
查看更多

同类化合物

腺苷-3’-磷酸 胸苷酰-(3'-5')-胸苷氰基乙基磷酰三酯 胸腺嘧啶脱氧核苷3-单磷酸铵盐水合物 胞啶-3'-单磷酸二钠盐 环(腺苷酰(3'-5')尿苷单磷酸酯) 尿苷酸 尿苷溴乙酰甲醇5'-二磷酸酯 尿苷氯乙酰甲醇5'-二磷酸酯 [(2R,3S,4R,5R)-5-(6-氨基嘌呤-9-基)-4-羟基-2-(羟基甲基)四氢呋喃-3-基]苯基磷酸氢酯 N-苯甲酰基-2'-脱氧-3'-胞苷酸2-氯苯基2-氰基乙基酯 8-[(E)-苄亚基氨基]-2'-脱氧腺苷3'-(磷酸二氢酯) 5-甲基-2'-脱氧胞苷-3'-磷酸 3'-(二氢磷酸)鸟嘌呤核苷 3'-(1-丁基磷酰)腺苷 2ˊ-脱氧胞苷-3ˊ-一磷酸 2-脱氧腺苷-3-单磷酸酯*铵 2'-脱氧鸟苷 3'-(磷酸二氢酯) 2'-脱氧腺苷酰-(3'-5')-2'-脱氧腺苷酰-(3'-5)-2'-脱氧腺苷 2'-脱氧-3'-胞苷酸二钠盐 2' -脱氧3' -磷酸游离酸 uridine 3'-(2,2,2-trichloroethyl)phosphate triethylammonium salt 5'-O-pivaloyl-2'-O-(tetrahydropyran-2-yl)uridin-3'-yl 2,2-difluoroethyl isopropyl phosphate 3'-O-(di-tert-butoxyphosphoryl)-6-N-benzoyladenosine 2',5'-di-O-tert-butyldimethylsilyluridine 3'-(2,2,2-trichloroethyl)phosphate α-L-threofuranosyl adenine-3′-monophosphate α-L-threofuranosyl thymine-3′-monophosphate N2-2-nitrobenzen-1-yl-2'-deoxyguanosine-3'-phosphate thymidine 3'-monophosphate 3'-(5'-deoxy-5-fluoro)uridylic acid mono[(2R)-2,3-dihydroxypropyl] ester guanosyl-(3',3')-uridine thymidine 3'-hexadecylphosphate Thymidine 3'-(1,2-dimyristoyl-sn-glycero-3-phosphate) Diethyl 5'-O-(tert-butyldimethylsilyl)-N6,N6-diethyl-2'-deoxyadenosine 3'-phosphate 9-β-D-Arabinofuranosylhypoxanthine-3'-phosphate 3'-Cytidylic acid, N-benzoyl-2'-deoxy-5'-O-(9-phenyl-9H-xanthen-9-yl)-, mono(2-chlorophenyl) ester Niacinamide adenylate 2'-deoxyadenosine-3'-triphosphate dCpdU 1-(O3-phosphono-β-D-arabinofuranosyl)-1H-pyrimidine-2,4-dione 2',5'-Di(tert-butyldimethylsilyl)-3'-(ethyl 4-(hydroxymethyl)phenyl phosphate)uridine 2',5'-Di(tert-butyldimethylsilyl)-3'-(ethyl 4-formylphenyl phosphate)uridine 2',5'-Di(tert-butyldimethylsilyl)-3'-(ethyl vinyl phosphate)uridine 2',5'-Di(tert-butyldimethylsilyl)-3'-(ethyl 4-(fluoromethyl)phenyl phosphate)uridine Phosphoric acid (2R,3R,4R,5R)-4-(tert-butyl-dimethyl-silanyloxy)-2-(tert-butyl-dimethyl-silanyloxymethyl)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-tetrahydro-furan-3-yl ester 1,2-dibromo-ethyl ester ethyl ester N(6)-(benzoyl)-2'-O-(tert-butyldimethylsilyl)adenosine 3'-(allyl 2-cyanoethyl phosphate) N6-benzoyl-3'-O-[bis(benzyloxy)phosphoryl]-2'-O-(4-methoxybenzyl)adenosine 2'-deoxyguanosine 3'-monophosphate ammonium salt Phosphoric acid dibenzyl ester (2R,3S,5R)-2-hydroxymethyl-5-(6-methylamino-purin-9-yl)-tetrahydro-furan-3-yl ester N6-methyl-2'-deoxyadenosine-3'-phosphate [(2R,3S,5R)-3-[(2,2-dicyano-3-hydroxypropoxy)-(2-methoxyethoxy)phosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl 2,2-dimethylpropanoate